Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SHAMAN PHARMACETICALS - SHMN - U.S. OTC -- Ignore unavailable to you. Want to Upgrade?

To: Mike Jafari who wrote (19)	4/26/1998 5:57:00 PM
From: kha vu	Read Replies (1) \| Respond to of 69

I just finished reading through the Annual Report for SHMN. In it they project that they should be able to clear the final FDA hurdle in early 1999 and expect to manufacture 28 million doses of Provir in 1999. They are presently pursuing a 2nd application for Provir to treat "travelers' diarhea" as well as the more serious forms that occur in AIDS patients; which the Phase tests have focused on. Provir is derived from the latex of the Croton tree. SHMN says they have already established a large stable source of the tree for raw materials. SHMN is currently preparing the NDA (new drug application) paperwork for submission to the FDA ASAP. They expect that due to the huge world-wide need for their product, the FDA will expedite approval as much as is possible. It would appear that te stock may well be languishing at its current level for yet a few more months, Taipan's expectations to the contrary. Taipan is newsletter which has website: taipanonline.com